Cardiometabolic Risk Factors in Men with Elevated Macroprolactin Content: A Pilot Study

Robert Krysiak; Witold Szkróbka; Bogusław Okopień

doi:10.1055/a-0902-4439

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2021; 129(01): 7-13
DOI: 10.1055/a-0902-4439

Article

Cardiometabolic Risk Factors in Men with Elevated Macroprolactin Content: A Pilot Study

Robert Krysiak

¹Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland

,

Witold Szkróbka

¹Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland

,

Bogusław Okopień

¹Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland

› Author Affiliations

Abstract

Background Macroprolactinemia is a condition associated with the presence of large amounts of high molecular weight complexes of prolactin. Despite high prevalence, clinical significance of macroprolactin remains poorly understood.

Objective The aim of this study was to assess cardiometabolic risk in men with isolated macroprolactinemia.

Methods The study population included 11 men with isolated macroprolactinemia, 14 subjects with monomeric hyperprolactinemia and 14 men with prolactin levels within the reference range. Glucose homeostasis markers, plasma lipids, as well as plasma levels of uric acid, high-sensitivity C-reactive protein (hsCRP), fibrinogen, homocysteine and 25-hydroxyvitamin D were determined in all included patients.

Results Compared to healthy counterparts, men with isolated macroprolactinemia had higher levels of 2-h postchallenge glucose, hsCRP and fibrinogen, lower levels of 25-hydroxyvitamin D and reduced insulin sensitivity. Patients with monomeric hyperprolactinemia were characterized by increased plasma levels of 2-h postchallenge glucose, triglycerides, uric acid, hsCRP, fibrinogen and homocysteine, reduced insulin sensitivity and decreased plasma concentrations of HDL cholesterol and 25-hydroxyvitamin D. Subjects with isolated macroprolactinemia differed from patients with monomeric hyperprolactinemia in postchallenge plasma glucose, insulin sensitivity, uric acid, hsCRP, fibrinogen, homocysteine and 25-hydroxyvitamin D. In men with monomeric hyperprolactinemia, uric acid, hsCRP, fibrinogen, homocysteine and 25-hydroxyvitamin D, while in men with elevated levels of macroprolactin, uric acid, hsCRP, fibrinogen and 25-hydroxyvitamin D correlated with a content of monomeric prolactin or macroprolactin, respectively, as well as with a degree of insulin sensitivity.

Conclusions The obtained results suggest that macroprolactinemia may increase cardiometabolic risk but to a lesser extent than monomeric hyperprolactinemia.

Key words

cardiovascular risk - macroprolactin - monomeric prolactin - risk factors

Full Text

References

References
1 Fahie-Wilson M, Smith TP. Determination of prolactin: The macroprolactin problem. Best Pract Res Clin Endocrinol Metab 2013; 27: 725-742
2 Kasum M, Orešković S, Čehić E. et al. Laboratory and clinical significance of macroprolactinemia in women with hyperprolactinemia. Taiwan J Obstet Gynecol 2017; 56: 719-724
3 Fahie-Wilson MN, John R, Ellis AR. Macroprolactin; High molecular mass forms of circulating prolactin. Ann Clin Biochem 2005; 42 (Pt 3) 175-192
4 Vallette-Kasic S, Morange-Ramos I, Selim A. et al. Macroprolactinemia revisited: A study on 106 patients. J Clin Endocrinol Metab 2002; 87: 581-588
5 Sinha YN. Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 1995; 16: 354-369
6 Shimatsu A, Hattori N. Macroprolactinemia: diagnostic, clinical, and pathogenic significance. Clin Dev Immunol 2012; 2012: 167132
7 Hattori N, Ishihara T, Saiki Y. Macroprolactinemia prevalence and aetiologies in a large group of hospital workers. Clin Endocrinol (Oxf) 2009; 71: 702-708
8 Bjoro T, Makrid L, Wergerland R. et al. Frequency of hyperprolactinemia due to large molecular weight prolactin (150–170 kD PRL). Scand J Clin Lab Invest 1995; 55: 139-147
9 Alfonso A, Rieniets KI, Vigersky RA. Incidence and clinical significance of elevated macroprolactin levels in patients with hyperprolactinemia. Endocr Pract 2006; 12: 275-280
10 Lu CC, Hsieh CJ. The importance of measuring macroprolactin in the differential diagnosis of hyperprolactinemic patients. Kaohsiung J Med Sci 2012; 28: 94-99
11 Vilar L, Naves LA, Freitas MC. et al. Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia. Minerva Endocrinol 2007; 32: 79-86
12 dos Santos Silva CM, Barbosa FR, Lima GA. et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring) 2011; 19: 800-805
13 Serri O, Li L, Mamputu JC. et al. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 2006; 64: 366-370
14 Berinder K, Nyström T, Höybye C. et al. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 2011; 14: 199-207
15 Jiang XB, Li CL, He DS. et al. Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study. Pituitary 2014; 17: 232-239
16 Jiang XB, He DS, Mao ZG. et al. BMI, apolipoprotein B/apolipoprotein A-I ratio, and insulin resistance in patients with prolactinomas: A pilot study in a Chinese cohort. Tumour Biol 2013; 34: 1171-1176
17 Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: Weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 1998; 48: 547-553
18 Schmid C, Goede DL, Hauser RS. et al. Increased prevalence of high body mass index in patients presenting with pituitary tumours: Severe obesity in patients with macroprolactinoma. Swiss Med Wkly 2006; 136: 254-258
19 Krysiak R, Szkróbka W, Okopień B. Different effects of atorvastatin on cardiometabolic risk factors in young women with and without hyperprolactinemia. J Clin Pharmacol 2019; 59: 83-89
20 Krysiak R, Szkróbka W, Okopień B. Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia. Pharmacol Rep 2018; 71: 61-66
21 Krysiak R, Okopień B. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels. Basic Clin Pharmacol Toxicol 2015; 116: 251-256
22 Gulcelik NE, Usman A. Macroprolactinaemia in diabetic patients. Neuro Endocrinol Lett 2010; 31: 270-274
23 Krysiak R, Kowalska B, Szkróbka W. et al. The association between macroprolactin levels and vitamin D status in premenopausal women with macroprolactinemia: A pilot study. Exp Clin Endocrinol Diabetes 2015; 123: 446-450
24 Krysiak R, Kowalska B, Szkróbka W. et al. A neutral effect of testosterone therapy on macroprolactin content in men with macroprolactinemia and late-onset hypogonadism. Pharmacol Rep 2016; 68: 139-143
25 Barth JH, Lippiatt CM, Gibbons SG. et al. Observational studies on macroprolactin in a routine clinical laboratory. Clin Chem Lab Med 2018; 56: 1259-1262
26 Vilar L, Fleseriu M, Bronstein MD. Challenges and pitfalls in the diagnosis of hyperprolactinaemia. Arq Bras Endocrinol Metabol 2014; 58: 9-22
27 Romijn JA. The chronic syndromes after previous treatment of pituitary tumours. Nat Rev Endocrinol 2016; 12: 547-556
28 Sherlock M, Ayuk J, Tomlinson JW. et al. Mortality in patients with pituitary disease. Endocr Rev 2010; 31: 301-342
29 Mounier C, Trouillas J, Claustrat B. et al. Macroprolactinaemia associated with prolactin adenoma. Hum Reprod 2003; 18: 853-857
30 Tamer G, Telci A, Mert M. et al. Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed. Endocrine 2012; 41: 138-143
31 Kinlay S, Egido J. Inflammatory biomarkers in stable atherosclerosis. Am J Cardiol 2006; 98: 2P-8P
32 Krysiak R, Okopień B, Herman Z. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003; 63: 1821-1854
33 Wang L, Song Y, Manson JE. et al. Circulating 25-hydroxyvitamin D and risk of cardiovascular disease: A meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes 2012; 5: 819-829
34 Papakonstantinou E, Lambadiari V, Dimitriadis G. et al. Metabolic syndrome and cardiometabolic risk factors. Curr Vasc Pharmacol 2013; 11: 858-879
35 iri-Tarino PW, Krauss RM. Diet, lipids, and cardiovascular disease. Curr Opin Lipidol 2016; 27: 323-328
36 Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin Endocrinol (Oxf) 2005; 62: 633-643
37 Olukoga AO. Macroprolactinemia is clinically important. J Clin Endocrinol Metab 2002; 87: 4833-4834
38 Krysiak R, Szkróbka W, Okopień B. A neutral effect of metformin treatment on macroprolactin content in women with macroprolactinemia. Exp Clin Endocrinol Diabetes 2017; 125: 223-228
39 Krysiak R, Szkróbka W, Okopień B. Sex-dependent effect of metformin on serum prolactin levels in hyperprolactinemic patients with type 2 diabetes: A pilot study. Exp Clin Endocrinol Diabetes 2018; 126: 342-348
40 Krysiak R, Kowalcze K, Szkrobka W. et al. The effect of metformin on prolactin levels in patients with drug-induced hyperprolactinemia. Eur J Intern Med 2016; 30: 94-98
41 Kavanagh L, McKenna TJ, Fahie-Wilson MN. et al. Specificity and clinical utility of methods for the detection of macroprolactin. Clin Chem 2006; 52: 1366-1372